Floatz logo

Incb099318

MSI-H/dMMR Tumors

Incyte CorporationPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the MSI-H/dMMR Tumors cohort.

Asset / SponsorPhaseRating
Incb099280
Incyte Corporation
Phase 1C

Same molecule, other indications

Incb099318 is also rated in:

PD-L1 Amplified Tumor (9p24.1)Dormant
CC
Indicative ·
43 / 100
View asset →
anal carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
squamous cell carcinoma of penisDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →